Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC boosted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 4.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,646 shares of the specialty pharmaceutical company’s stock after acquiring an additional 108 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $325,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. ST Germain D J Co. Inc. acquired a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at approximately $40,000. Covestor Ltd boosted its stake in Jazz Pharmaceuticals by 676.5% during the 3rd quarter. Covestor Ltd now owns 396 shares of the specialty pharmaceutical company’s stock valued at $51,000 after purchasing an additional 345 shares in the last quarter. Spire Wealth Management boosted its stake in Jazz Pharmaceuticals by 128.6% during the 3rd quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 238 shares in the last quarter. Headinvest LLC bought a new position in Jazz Pharmaceuticals during the 3rd quarter valued at $56,000. Finally, Signaturefd LLC boosted its stake in Jazz Pharmaceuticals by 85.7% during the 3rd quarter. Signaturefd LLC now owns 546 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 252 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 1,936 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares in the company, valued at $1,000,668.96. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CFO Philip L. Johnson bought 12,000 shares of the business’s stock in a transaction on Friday, March 1st. The shares were bought at an average cost of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at $3,342,063.80. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO Patricia Carr sold 1,936 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the transaction, the chief accounting officer now owns 8,364 shares in the company, valued at $1,000,668.96. The disclosure for this sale can be found here. 4.40% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $110.58 on Friday. The stock has a market cap of $6.97 billion, a PE ratio of 18.07, a price-to-earnings-growth ratio of 1.58 and a beta of 0.59. The business has a fifty day simple moving average of $121.21 and a 200-day simple moving average of $123.21. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37. Jazz Pharmaceuticals plc has a 12 month low of $110.42 and a 12 month high of $147.14.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by ($0.04). The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. On average, sell-side analysts anticipate that Jazz Pharmaceuticals plc will post 16.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on JAZZ shares. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 30th. Piper Sandler increased their price target on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $180.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday. UBS Group reduced their price objective on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating for the company in a research note on Friday, March 1st. Finally, Barclays reduced their price objective on Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating for the company in a research note on Friday, March 1st. Two research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $195.08.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.